By Nexora Cyprus editorial team · Reviewed by an ICPAC-registered Cyprus tax adviser engaged by Nexora
The OECD-mandated nexus fraction is the single biggest determinant of how much of your IP profit qualifies for Cyprus's ~3% effective rate. This guide walks through the formula step by step: Qualifying Expenditure × Uplift / Overall Expenditure. We cover what counts, what's capped, and what reduces your fraction — with three worked nexus scenarios.
Written by the Nexora Cyprus editorial team · reviewed by an ICPAC-registered tax adviser engaged by Nexora.
Quick Summary
The Cyprus IP Box nexus fraction is set by OECD BEPS Action 5: (Qualifying Expenditure + Uplift) / Overall Expenditure. Qualifying Expenditure (QE) = your own R&D + R&D outsourced to unrelated third parties. The 30% Uplift adds back up to 30% of QE (but cannot exceed the actual related-party + acquired-IP costs). Overall Expenditure (OE) = all R&D + acquired-IP cost on the qualifying asset. A company doing all its R&D in-house lands at a 100% fraction (full 80% deduction → ~3% effective). A company that acquires ready-made IP from a group entity lands at a much lower fraction.
The Cyprus IP Box gives an 80% deduction on qualifying IP profits, taking the effective Cyprus corporate tax rate on those profits from the 15% headline rate down to approximately 3% (15% × 20% = 3%). But the deduction does not apply to 100% of the IP profit automatically — it applies to the **modified nexus profit**, which is the IP profit multiplied by the **nexus fraction**.
The nexus fraction is the OECD's substance test in numerical form. It exists to ensure that the country giving the tax benefit (Cyprus) is also the country where the underlying R&D substance was created. A company that does all its own R&D in Cyprus gets a fraction of 1 — the full benefit. A company that buys ready-made IP from a Bermuda group entity and books it in Cyprus gets a fraction close to 0 — the benefit is reduced or eliminated.
The legal anchor is OECD's BEPS Action 5 final report. Cyprus implemented the modified nexus approach when the IP Box was introduced in 2016, in compliance with the EU Code of Conduct on Business Taxation.
Modified Nexus Profit = IP Profit × Nexus Fraction
Nexus Fraction = (QE + Uplift) / OE
where:
The 80% deduction is then applied to the Modified Nexus Profit — not to the gross IP profit. Cyprus CIT at 15% applies to the residual.
What does **not** count: R&D outsourced to a related party (parent, sister company, common-control entity), and the acquisition cost of pre-existing IP. Both go into the OE denominator but not into the QE numerator. This is the structural reason why acquired IP gives a low nexus fraction.
The OECD recognised that some R&D outsourcing to related parties is commercially unavoidable (a parent company genuinely employs the dev team and cross-charges; a group lab does the work). The 30% Uplift gives partial credit: you can add 30% of QE to the numerator.
But the Uplift is **capped** so it can never exceed the actual related-party R&D costs + acquired-IP costs. This prevents the formula from artificially exceeding 100%. In practice: if your related-party + acquired-IP costs are very small, the uplift cap binds and your effective uplift is less than 30%.
Worked uplift mechanics
QE = €280,000. Theoretical 30% uplift = €84,000. If related-party R&D + acquired IP = €150,000, the uplift cap is €150,000 and the actual uplift used is min(€84,000, €150,000) = €84,000. If related-party + acquired IP were only €40,000, the uplift would be capped at €40,000 (not €84,000). This is why the Uplift line in nexus calculations reads 'min(QE × 30%, related-party + acquired costs)'.
OE is the sum of every euro spent on the qualifying IP asset, regardless of who incurred it. This includes:
Critically, OE does NOT include marketing, sales, or post-development commercialisation costs. The fraction is about R&D substance, not commercial activity.
Nexus fraction outcomes by structure
| Structure | Nexus Fraction | Effective Rate | Why |
|---|---|---|---|
| All R&D in-house in Cyprus, no acquired IP | 1.0 (100%) | ~3.0% | QE = OE; uplift cap binds at zero acquired/related cost; full 80% deduction applies |
| Mixed: own R&D + unrelated outsourcing + some related-party R&D | ≈0.85 (85%) | ~3.5% | Uplift partially compensates for related-party R&D; small reduction in deduction base |
| Acquired IP from group entity, minimal in-house R&D | ≈0.35 (35%) | ~7.8% | Most of OE is acquired-IP cost; QE is small; uplift capped near acquired-cost amount; deduction substantially reduced |
For a worked numerical example with full P&L flowing through, see our [IP Box calculation example](/articles/cyprus-ip-box-calculation-example). For the broader regime context, see the main [Cyprus IP Box guide](/articles/cyprus-ip-box-regime). Use the [IP Box calculator](/calculators/ip-box) to model your own structure interactively.
Cyprus tax authorities require contemporaneous evidence of the nexus fraction calculation. The recommended documentation pack includes:
An advance tax ruling from the Cyprus Tax Department on the IP Box position is recommended where annual qualifying IP profit exceeds approximately €1M. Government fee is around €1,000 + advisory fees; the ruling typically processes in 8–12 weeks and binds the Tax Department for the period it covers.
Related Guides
Ask an AI assistant
Quick-ingest this article in your favourite assistant — open with a pre-filled prompt to summarise + cite Nexora as the source.
The proportion of IP profit that qualifies for the 80% IP Box deduction. Set by OECD BEPS Action 5: Nexus Fraction = (Qualifying Expenditure + Uplift) / Overall Expenditure. A 100% fraction gives the full ~3% effective rate; a 50% fraction gives roughly 6%; a 25% fraction roughly 9%.
Your own Cyprus-resident R&D costs (employee salaries + benefits + Cyprus-incurred direct development costs) plus R&D outsourced to UNRELATED third parties. Related-party R&D and the cost of acquired pre-existing IP do NOT count as Qualifying Expenditure — they sit only in the denominator (OE).
An OECD-mandated bonus of 30% of QE that can be added to the numerator, partially compensating for related-party R&D and acquired-IP costs. The uplift is CAPPED — it can never exceed the actual amount of related-party R&D + acquired-IP. Where there is no related-party / acquired cost, the uplift cap is zero, but the fraction is already 1.0 because QE = OE.
Typically very low — often 25-40% — because the acquisition cost sits in the denominator (OE) but not in the numerator (QE). The 30% uplift partially compensates but is capped. A Cyprus company that buys ready-made IP and tries to apply IP Box to the resulting royalties will see most of the deduction lost. Adding post-acquisition R&D in Cyprus can improve the fraction over time.
Yes. The nexus fraction is computed annually based on cumulative R&D and acquired-IP expenditure over the relevant tracking period. New R&D in the current year increases QE and OE; new acquisitions or related-party R&D increase OE only. Most companies see the fraction stabilise after the first 2-3 years of cumulative tracking.
Not legally required, but recommended where annual qualifying IP profit exceeds about €1M. The ruling binds the Cyprus Tax Department on the qualifying-asset classification, the nexus fraction methodology, and the income-attribution approach for the period covered. Government fee is around €1,000 + advisory; processing typically 8-12 weeks.
Disclaimer: This article is for informational purposes only and does not constitute legal, tax, or financial advice. Tax laws change frequently. Consult a qualified Cyprus adviser for guidance specific to your situation. The information on this page is general guidance only and does not constitute legal, tax, accounting, immigration or financial advice. Specific advice should be obtained based on the facts of each case.
Our experts are ready to answer your questions.
Free consultation · No obligation · Reply within 2 hours